ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024

Lonigutamab is the first subcutaneous anti-IGF-1R to demonstrate clinical responses in thyroid eye disease patients LOS ANGELES, May 29, 2024 -- ACELYRIN, INC. , a late-stage clinical biopharma...

Related Keywords

United States ,Jules Stein Eye Institute ,California ,Boston ,Massachusetts ,San Francisco Bay ,Los Angeles ,Shoaib Ugradar ,Tyler Marciniak ,Linkedin ,Exchange Commission ,Department Of Orbital ,University Of California ,Nasdaq ,Endocrine Society Annual Meeting ,Endocrine Society ,Annual Meeting ,Oculoplastic Surgery ,Private Practice ,Eye Disease ,Annual Report ,Investor Relations ,